Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 17, 2026

Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally

View original at globenewswire.com
Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally Stellantis, Wayve, and Uber are collaborating to develop and deploy L4 driverless mobility services By combining Stellantis’ world-class vehicle L4-Ready Platforms™, Wayve’s advanced AI Driver…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Successfully scaling autonomous mobility requires seamlessly combining the right vehicles, technology, and platform.

    60% confidence

  • Wayve's AI driving technology is designed to adapt across different regions and driving conditions without relying on city-by-city mapping or re-engineering, enabling faster and more cost-effective expansion.

    60% confidence

  • Uber has completed more than 75 billion trips since its founding in 2010.

    60% confidence

  • The three-way partnership signals industry convergence around Wayve's technology as the leading approach to scale autonomous vehicles globally.

    60% confidence

  • The collaboration will deliver smarter, safer, and more efficient mobility by combining Stellantis' L4-Ready Platforms with Wayve's adaptive AI and Uber's global network to accelerate AV deployment that meets real customer needs at scale.

    60% confidence

Data points we hold from this source

Uber Technologies · trips completed75 billion_trips
Uber Technologies · founding year2010 year
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally — Source | Via News | Finance Via News